Harold J. Burstein, MD, PhD, a medical oncologist at the Dana-Farber Cancer Institute, explains how ovary suppression is done in patients with breast cancer. This is a particularly important treatment for younger women who still wish to have children one day.
Harold J. Burstein, MD, PhD, a medical oncologist at the Dana-Farber Cancer Institute, explains how ovary suppression is done in patients with breast cancer. This is a particularly important treatment for younger women who still wish to have children one day.
Ovary suppression can be done in 1 of 2 ways, and both have proven successful in a number of cases and trials. The first option is to completely remove the ovaries surgically. This is not the preferred method, but it has become a standard when a patient does not wish to continue with the second option.
The other way to perform ovary suppression involves gonadotropin-releasing hormone (GnRH) agonist drugs given via injections monthly or once every 3 months. The is typically used first in younger women and tolerance to the drugs will be displayed between 6-12 months of the initial shot. From there, patients can choose to stay on this treatment plan or have the ovaries surgically removed.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen